卡瑞利珠单抗联合经动脉化疗栓塞及索拉非尼或仑伐替尼治疗不可切除肝细胞癌：一项多中心回顾性研究

Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study.

作者信息

Jiang Xiumei, Wang Pan, Su Ke, Li Han, Chi Hao, Wang Fei, Liu Yu, Xu Ke

机构信息

Department of Oncology, Chongqing General Hospital, Chongqing, 401147, China.

Clinical Skills Center, The Affliated Hospital of Southwest Medical University, Luzhou, 646000, China; Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.

出版信息

Ann Hepatol. 2024 Sep 12;30(2):101578. doi: 10.1016/j.aohep.2024.101578.

DOI:10.1016/j.aohep.2024.101578

PMID:39276984

Abstract

INTRODUCTION AND OBJECTIVES

We initiated this study to explore the efficacy of camrelizumab combined with transcatheter arterial chemoembolization (TACE) plus sorafenib or lenvatinib versus TACE plus sorafenib or Lenvatinib for unresectable hepatocellular carcinoma (HCC).

MATERIALS AND METHODS

From June 2019 to November 2022, 127 advanced HCC patients were retrospectively analyzed in this study. This consisted of 44 patients that received camrelizumab plus TACE plus sorafenib or lenvatinib (triple therapy group) and 83 patients that received TACE plus sorafenib or lenvatinib (double treatment group). The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two patient groups.

RESULTS

Our findings demonstrated that patients received the triple therapy exhibited superior median OS (15.8 vs. 10.3 months, P=0.0011) and median PFS (7.2 vs. 5.2 months, P=0.019) compared to the double treatment group. In addition, the triple therapy group exhibited better 6-month (93.5% vs. 66.3%), 12-month (67.2% vs. 36.3%), and 24-month (17.2% vs. 7.6%) survival rates than the double treatment group. However, the ORR (43.2% vs. 28.9%, P = 0.106) and DCR (93.2% vs. 81.9%, P = 0.084) of the two groups were similar. Subgroup analysis showed that compared with the double treatment group, the triple therapy group had a better mOS for HCC with HBV (15.8 vs. 9.6 months, P = 0.0015) and tumor diameter ≥ 5cm (15.3 vs. 9.6 months, P = 0.00055).

CONCLUSIONS

Camrelizumab plus TACE and sorafenib or lenvatinib may be a promising treatment approach for the clinical management of unresectable HCC patients.

摘要

引言与目的

我们开展这项研究旨在探讨卡瑞利珠单抗联合经动脉化疗栓塞术（TACE）加索拉非尼或仑伐替尼与TACE加索拉非尼或仑伐替尼治疗不可切除肝细胞癌（HCC）的疗效。

材料与方法

2019年6月至2022年11月，本研究对127例晚期HCC患者进行回顾性分析。其中44例患者接受卡瑞利珠单抗加TACE加索拉非尼或仑伐替尼（三联治疗组），83例患者接受TACE加索拉非尼或仑伐替尼（双联治疗组）。比较两组患者的总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）和疾病控制率（DCR）。

结果

我们的研究结果表明，与双联治疗组相比，接受三联治疗的患者中位OS（15.8个月对10.3个月，P = 0.0011）和中位PFS（7.2个月对5.2个月，P = 0.019）更优。此外，三联治疗组的6个月（93.5%对66.3%）、12个月（67.2%对36.3%）和24个月（17.2%对7.6%）生存率均高于双联治疗组。然而，两组的ORR（43.2%对28.9%，P = 0.106）和DCR（93.2%对81.9%，P = 0.084）相似。亚组分析显示，与双联治疗组相比，三联治疗组对于HBV相关HCC（15.8个月对9.6个月，P = 0.0015）和肿瘤直径≥5cm的HCC（15.3个月对9.6个月，P = 0.00055）患者的中位OS更好。